The Biorepository Core (BioC) complements the services provided by the Pharmacology Core and provides the laboratory-based, epidemiological, and clinical investigators with a diverse selecfion of human fissue specimens necessary for research. A major goal of the Core is to accelerate the transifion from basic science to clinical research by providing access to well characterized human tissue. Within the established rules ofthe Human Invesfigafive Committee and HIPAA, the Core performs several funcfions. These include patient consenfing, tissue collection, tissue processing, banking and storage, retrieval, and transfer of fresh frozen and formalin fixed paraffin embedded human tissue obtained from the surgical suites and endoscopic units of KCI. Key services include case identification by diagnostic categories and subsequent retrieval of pathology materials (reports, blocks, slides, banked fixed and frozen materials), providing complete and accurate pathological diagnosis and interpretafions.
; BioC services enable basic science, population science, and clinical researchers to expand further into translational research. This is accomplished by the Core providing unique malignant and benign focused tissues from its tissue bank. Additionally, KCI investigators are able to use the BioC to rapidly evaluate targets and biomarkers relevant to cancer cure. Tissues acquired through this Core come from a diverse population, aiding research into health disparities.
|Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963|
|An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605|
|Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56|
|Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55|
|Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58|
|Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703|
|Wang, Zhaoxian; Sau, Samaresh; Alsaab, Hashem O et al. (2018) CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 14:1441-1454|
|Vaishampayan, Ulka (2018) Advantages and Adversities of the Weighted Toxicity Score. Clin Cancer Res 24:4918-4920|
|Kim, Seongho; Wong, Weng Kee (2018) Extended two-stage adaptive designs with three target responses for phase II clinical trials. Stat Methods Med Res 27:3628-3642|
|Ravindra, Manasa; Wilson, Mike R; Tong, Nian et al. (2018) Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor ? and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis. J Med Chem 61:4228-4248|
Showing the most recent 10 out of 826 publications